Eligible subjects are invited to participate in the Testosterone in Cancer Survivors Study, which is a randomized placebo-controlled research study in men, ages 18-50, who have received chemotherapy and/or radiation therapy for their cancer and are now off-treatment and in remission for at least 1 year. Investigators are interested in evaluating whether testosterone, an FDA-approved drug, compared to placebo, (looks like testosterone but doesn’t activity in cancer survivors who report fatigue and have low testosterone. The National Cancer Institute, a branch of the National Institutes of Health, is providing the funding for the research study. If participants are found to be eligible and agree to enroll in the study, they will attend up to 8 study visits at the Brigham and Women’s Hospital over approximately 9 months.

Study activities include:

• General questions about your health
• Blood draws
• Physical exams
• Questionnaires
• Muscle strength tests
• Physical function tests
• Body imaging to look at your body muscle and fat
• Testosterone or placebo injections